PDCD1 and neoplasm: A recent study performed tumor immunoassays through two syngeneic mouse model (CT‐26 and Colon 26), which have similar genetic backgrounds with different sensitivities to anti‐PD1 therapy, revealing the underlying mechanisms of anti‐PD1 responses.